PARP inhibitors (PARPi) leverage this synthetic lethality and are US FDA approved to treat germline BRCA1 or BRCA2-mutant breast, ovarian, pancreatic, and prostate cancers [1,2,3,4,5]. Here, BRCA1 is linked to prostate cancer.